Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Eyepoint Pharmaceuticals Inc
EYPTCurrent price
5.68 USD
+0.13 USD (+2.25%)
Last closed
4.62 USD
Company
eyepointpharma.com
ISIN
US30233G2093
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
390 035 968 USD
Yield for 12 month
-66.52 %
1Y
3Y
5Y
10Y
15Y
EYPT
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Address: 480 Pleasant Street, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
33.00 USDP/E ratio
–Dividend Yield
–Current Year
+43 273 000 USD
Last Year
+46 018 000 USD
Current Quarter
+11 588 000 USD
Last Quarter
+10 524 000 USD
Current Year
+39 561 000 USD
Last Year
+41 386 000 USD
Current Quarter
+10 772 000 USD
Last Quarter
+9 788 000 USD
Key Figures EYPT
1 year
3 years
5 years
10 years
EBITDA
-144 314 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-23.57 %
PEG Ratio
–
Return On Equity TTM
-43.42 %
Wall Street Target Price
33.00 USD
Revenue TTM
43 273 000 USD
Book Value
4.93 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-17.40 %
Dividend Yield
–
Gross Profit TTM
21 089 000 USD
Earnings per share
-2.32 USD
Diluted Eps TTM
-2.32 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics EYPT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History EYPT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
09.12.2020
Stock Valuation EYPT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.75
Price Sales TTM
9.01
Enterprise Value EBITDA
-11.49
Price Book MRQ
1.13
Financials EYPT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators EYPT
For 52 weeks
3.91 USD
21.26 USD
50 Day MA
6.03 USD
Shares Short Prior Month
10 828 642
200 Day MA
8.18 USD
Short Ratio
14.20
Shares Short
10 928 768
Short Percent
17.96 %
BeatStart